use of Amritadi tablet in management of side effects of radiotherapy in oral cancer

Clinical evaluation of Amritadi tablet as palliative care in management of side effects of radiotherapy in oral squamous cell carcinoma w.s.r to tobacco induced oral cancer

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050379

Enrollment

Registered

2023-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: Amritadi tablet: Amritadi tablet having aamlaki guduchi ashwagandh Tulsi pupali shudha gugulu as contain dose: 2tablet 4 times per day route: oral Duration: 30 days Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: Patient diagnosed with oral squamous cell carcinoma Patient sign and symptoms of oral suamous cell carcinoma Post surgical Post chemotherapy TNM criteria T1-13 N1-N3 M0

Exclusion criteria

Exclusion criteria: Age below 18 or above 60 year Metastasis Uncontrolled DM or HTN Hiv HbsAg cardiac and renal diseases Total Trismus

Design outcomes

Primary

Measure	Time frame
primary outcome will assess on based of subjective and objective criteria like pain in oral cavity dysphagia irregular bowel habit anorexia odynophegia flatulence Trismus oral mucositis weight And patient will get relief in side effects of radiotherapyTimepoint: 30 days	—

Secondary

Measure	Time frame
Quality of life of cancer patients will be improvedTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDrVipulkumar V sangani

Government akhand Anand ayurveda college and hospital

drvipulvsangani@gmail.com9998960732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026